Tevogen Bio Holdings Inc (TVGN)
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. Its lead program, TVGN 489, has completed a Phase 1 clinical trial in ambulatory high-risk adult COVID-19 patients and is also being evaluated in Phase 1 for acute SARS-CoV-2 patients with B-cell cancer immune suppression, as well as for Long COVID prevention and treatment. The company’s pipeline also includes TVGN 920 for cervical cancer, TVGN 960 for oropharyngeal cancer, TVGN 601 for multiple sclerosis, TVGN 930 for Epstein-Barr virus-associated lymphomas, and TVGN 116 for hepatitis B, each currently in preclinical development. Founded in 2020 and headquartered in Warren, New Jersey, the company changed its name from Tevogen Bio Inc. in February 2024.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TVGN
|
$9.05
|
15.8% Upside
|
Fair
|
$100 1,180.4% Upside
|
Not available
|
Bargain
|
Fair
|
0.0%
|
November 13, 2026
|
50.855 M
|
68.016 M
|
14.1%
|
29.8%
|
-58.5
|
52.3%
|
